Comparative Pharmacology
Head-to-head clinical analysis: DIUPRES 500 versus LOPRESSIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUPRES 500 versus LOPRESSIDONE.
DIUPRES-500 vs LOPRESSIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.
Lopressidone is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, with higher affinity for 5-HT2A than D2, and also blocks alpha1-adrenergic and H1 histamine receptors.
Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.
Oral: 5 mg twice daily, titrate as tolerated up to 20 mg twice daily. Maximum 40 mg per day.
None Documented
None Documented
Reserpine: 50-100 hours (prolonged; clinical effect persists for days due to irreversible MAO depletion). Hydrochlorothiazide: 6-15 hours (biphasic; terminal phase reflects renal elimination).
12-15 hours; allows once-daily dosing, but steady-state reached in ~3-5 days.
Renal: ~50% (primarily hydrochlorothiazide), Fecal: ~50% (primarily reserpine).
Renal: ~60% (as unchanged drug); Fecal: ~30% (as metabolites); Biliary: minor (<5%).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination